A61K 2039/828
Stomach
Official title: {Stomach}
A61K2039/828 (Stomach) appears on 31 US grants and 67 published applications in this corpus.
Search patents in A61K- Granted patents
- 31
- Published applications
- 67
- Assignees
- 36
- Inventors
- 137
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 1 |
| 2015 | 2 | 1 |
| 2016 | 0 | 0 |
| 2017 | 1 | 2 |
| 2018 | 1 | 4 |
| 2019 | 1 | 4 |
| 2020 | 4 | 5 |
| 2021 | 2 | 9 |
| 2022 | 2 | 8 |
| 2023 | 5 | 8 |
| 2024 | 6 | 21 |
| 2025 | 6 | 0 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Fusion peptide vaccines15 Sep 2026US 12,734,225 B2Treos Bio Limited
- Peptides displayed by HLA for use in immunotherapy against different types of cancers3 Jun 2025US 12,318,407 B2Immatics Biotechnologies GmbH
- Peptides displayed by HLA for use in immunotherapy against different types of cancers6 May 2025US 12,290,530 B2Immatics Biotechnologies GmbH
- Peptides displayed by HLA for use immunotherapy against different types of cancers29 Apr 2025US 12,285,443 B2Immatics Biotechnologies GmbH
- Peptides displayed by HLA for use immunotherapy against different types of cancers15 Apr 2025US 12,274,716 B2Immatics Biotechnologies GmbH
- Methods for preventing the development of a gastric disease associated with helicobacter pylori infection without eradicating the infection and for the assessment of the risk of developing such disease2 Apr 2026US 2026/0091099 A1
- Novel mutant of recombinant ganoderma lucidum immunomodulatory protein and use thereof26 Dec 2024US 2024/0424071 A1Changchun Intellicrown Pharmaceutical Co., Ltd.
- Peptides displayed by hla for use in immunotherapy against different types of cancers14 Nov 2024US 2024/0374640 A1Immatics Biotechnologies GmbH
- Peptides displayed by hla for use in immunotherapy against different types of cancers14 Nov 2024US 2024/0374642 A1Immatics Biotechnologies GmbH
- Intracellular delivery of biomolecules to modify immune response14 Nov 2024US 2024/0374654 A2Stemcell Technologies Canada Inc.
Most cited
By later US patents
- Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers17US 9,132,177 B2Immatics Biotechnologies GmbH · 2015
- Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers13US 10,159,725 B2Immatics Biotechnologies GmbH · 2018
- Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers7US 10,400,011 B2Immatics Biotechnologies GmbH · 2019
- Antibody constructs for CLDN18.2 and CD36US 11,692,031 B2Amgen Inc. · 2023
- Chimeric antigen receptor targeting human NKG2DL and methods of preparing said receptor and pharmaceutical composition3US 11,090,335 B2Nanjing Kaedi Biotherapeutics Ltd. · 2021